Connect with us


First-ever launch of Linagliptin + Dapagliflozin + Metformin Hydrochloride (SR) by Theon Pharmaceutical for managing type 2 diabetes in India



Theon Pharmaceutical launches Linagliptin + Dapagliflozin + Metformin Hydrochloride (SR) for type 2 diabetes management for the first time in India

Theon Pharma, a leading pharmaceutical company, has launched a groundbreaking pharmaceutical drug combination for the management of type 2 diabetes in India. The combination, developed in compliance with DCGI standards and clinical trials, consists of a first-time combination of linagliptin and dapagliflozin, along with metformin hydrochloride. This new drug aims to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise.

Amit Bansal, Managing Director of Theon Pharmaceuticals Ltd, highlighted the benefits of this fixed-dose combination tablet, including safer and sustained glycemic control, reduction in FPG, PPG and HbA1c levels, improved insulin resistance and beta cell function, weight reduction, and cost-effectiveness. The combination aligns with the 2018 ICMR guidelines for the management of type 2 diabetes, emphasizing the importance of metformin hydrochloride, DPP4 inhibitors, and SGLT2 inhibitors in treatment algorithms.

The combination of linagliptin, dapagliflozin, and metformin hydrochloride has been deemed the best triple anti-diabetic combination due to their unique properties. Linagliptin is effective in inhibiting enzymes and has excellent renal safety, while dapagliflozin has shown benefits in reducing the risk of heart failure events and cardiovascular mortality. Metformin, when combined with the other two drugs, helps lower the risk of death in patients with type 2 diabetes and heart disease.

Overall, this new pharmaceutical drug combination represents a significant advancement in the treatment of type 2 diabetes and offers patients a comprehensive and effective approach to managing their condition. With the potential to improve glycemic control, reduce complications, and enhance overall quality of life, this innovative treatment option holds promise for individuals living with type 2 diabetes in India.

Click to comment

You must be logged in to post a comment Login

Leave a Reply